HR 1734 United States House · 118th Congress

TRANQ Research Act of 2023

The TRANQ Research Act of 2023 requires the National Institute of Standards and Technology (NIST) to coordinate research on illicit drugs containing xylazine, novel synthetic opioids, and other concerning substances. The bill mandates NIST to develop faster detection methods, create data tools for identifying these substances, and consult with agencies like the DEA, CDC, and National Institute on Drug Abuse to establish safe handling practices. NIST must also form partnerships with universities, federal labs, and the private sector to improve detection capabilities. Within one year, NIST must report to Congress on its implementation, and the Comptroller General must conduct a study on federal capabilities to respond to new psychoactive substances, reporting within two years.
Sub-Topics: Substance Abuse
Bill status signed all 5 stages cleared
Introduction
Mar 2023
Committee Review
May 2023
House Passage
Dec 2023
Senate Passage
Jun 2023
Signed into Law
Dec 2023
Introduced Mar 23, 2023 Signed Dec 19, 2023
Maddy AI version diff · 2 comparisons

What changed between versions

Engrossed in House Enrolled Bill · 7 edits
MODERATE
The Enrolled version of HR 1734 broadens the bill's scope by replacing 'emerging substances of concern in illicit drugs' with 'new psychoactive substances' throughout, removes references to 'illicit drugs' from several provisions, and significantly expands who NIST must consult (adding DEA, CDC, NIDA, State fusion centers, intergovernmental organizations, and others). A new Section 3 requires the GAO to conduct a two-year study of federal, state, and local capabilities to detect new psychoactive substances. The graduate research provision was softened from 'provide opportunities' to 'encourage...when practicable.'
SCOPE

The term 'emerging substances of concern in illicit drugs' was replaced with 'new psychoactive substances' throughout the bill, broadening the scope beyond illicit drugs to include any new psychoactive substance.

A new Section 3 requires the Comptroller General (GAO) to conduct a study evaluating the capabilities of Federal, State, and local agencies to detect and identify new psychoactive substances, including their technologies, timeframes, facilities, and federal grant programs. A report is due within 2 years of enactment.

The collaborative partnerships provision (subsection 4) was broadened from listing specific entity types to 'other government agencies and persons engaged in related research and development,' and added 'public health agencies' and 'intergovernmental organizations' as potential partners.

REQUIREMENT

The NIST convening requirement (subsection 3) was expanded to explicitly name DEA, CDC, NIDA, Federal laboratories, States and territories, State fusion centers, the private sector, intergovernmental organizations, institutions of higher education, and nonprofit organizations as parties to consult with. 'Data-sharing' was added to the list of activities.

The graduate research provision was softened from requiring NIST to 'provide opportunities for graduate and postgraduate research on the detection and identification of xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs' to merely 'encourage graduate and post-graduate research to include detection and identification of xylazine and other new psychoactive substances in relevant course studies when practicable.'

TECHNICAL

Definitions were reorganized from subsection (c) to subsection (a). The standalone 'NIST' definition was removed and replaced with an 'Institute' definition. Security controls language was modified to add 'as the Director considers appropriate and consistent with applicable provisions of law.'

The short title was updated to include 'of 2023' and the report section was renumbered from Section 3 to subsection (d) of Section 2.

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
27
Key actions
7
Committee
3
Amendments
6
Dec 19, 2023
Signed into law
Signed by President.
executive
Dec 4, 2023
Introduced
On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
lower
Dec 4, 2023
Lower · Passed
Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
lower
Dec 4, 2023
Introduced
DEBATE - The House proceeded with forty minutes of debate on the motion to suspend the rules and agree to the Senate amendment to H.R. 1734.
lower
Dec 4, 2023
Introduced
Mr. Lucas moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H6087-6089)
lower
Jun 22, 2023
Upper · Passed
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S2250-2251)
upper
Jun 22, 2023
Upper · Passed
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S2250-2251)
upper
May 11, 2023
Introduced
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 425 - 0 (Roll no. 212). (text: 5/9/2023 CR H2149)
lower
May 11, 2023
Lower · Passed
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 425 - 0 (Roll no. 212). (text: 5/9/2023 CR H2149)
lower
May 9, 2023
Introduced
Mr. Miller (OH) moved to suspend the rules and pass the bill, as amended.
lower
May 5, 2023
Lower · Passed
Reported (Amended) by the Committee on Science, Space, and Technology. H. Rept. 118-50.
lower
Mar 29, 2023
Introduced
Ordered to be Reported (Amended) by the Yeas and Nays: 36 - 0.
lower
Mar 29, 2023
Lower · Passed
Committee Consideration and Mark-up Session Held.
lower
Mar 23, 2023
Committee
Referred to the House Committee on Science, Space, and Technology.
lower
Mar 23, 2023
Introduced
Introduced in House
lower
1 primary · 25 co-sponsors

Sponsors